Table-III.
The medications administered in COVID-19 suspected and confirmed patients with normal or abnormal liver function.
| Drugs administered | % of suspected cases (n=20) | % of confirmed COVID-19 cases | P1 | P2 | ||
|---|---|---|---|---|---|---|
|
| ||||||
| All cases (n=53) | Normal liver function (n=17) | Abnormal liver function (n=36) | ||||
| Antivirals | ||||||
| Lopinavir/ritonavir | 5 (25%) | 33 (62.3%) | 10 (58.8%) | 23 (63.9%) | 0.723 | 0.004 |
| Arbidol | 16 (80%) | 41 (77.4%) | 11 (64.7%) | 30 (83.3%) | 0.130 | 0.808 |
| Ribavirin | 6 (30%) | 14 (26.4%) | 3 (17.6%) | 11 (30.6%) | 0.320 | 0.759 |
| Oseltamivir | 1 (5%) | 10 (18.9%) | 4 (23.5%) | 6 (16.7%) | 0.551 | 0.140 |
| Interferon | 2 (10%) | 12 (22.6%) | 3 (17.6%) | 9 (25%) | 0.550 | 0.221 |
| Chloroquine phosphate/Plaquenil | 1 (5%) | 12 (22.6%) | 2 (20%) | 10 (27.8%) | 0.194 | 0.079 |
| Antibiotics | ||||||
| Moxifloxacin | 16 (80%) | 44 (83.0%) | 12 (70.6%) | 32 (88.9%) | 0.390 | 0.885 |
| Azithromycin | 7 (35%) | 33 (62.3%) | 12 (70.6%) | 21 (58.3%) | 0.390 | 0.037 |
| Beta-lactam | 9 (45%) | 16 (30.2%) | 3 (17.6%) | 13 (36.1%) | 0.172 | 0.234 |
| Methyl predisolone | 5 (25%) | 34 (64.2%) | 8 (47.1%) | 26 (72.2%) | 0.075 | 0.003 |
P1 represents the statistical difference between the normal and abnormal liver function groups of 53 confirmed COVID-19 patients, and P2 represents the statistical difference between the COVID-19 suspected and confirmed patients.